US3798209A
(en)
|
1971-06-01 |
1974-03-19 |
Icn Pharmaceuticals |
1,2,4-triazole nucleosides
|
USRE29835E
(en)
|
1971-06-01 |
1978-11-14 |
Icn Pharmaceuticals |
1,2,4-Triazole nucleosides
|
US3852267A
(en)
|
1972-08-04 |
1974-12-03 |
Icn Pharmaceuticals |
Phosphoramidates of 3{40 ,5{40 -cyclic purine nucleotides
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
NL8403224A
(nl)
|
1984-10-24 |
1986-05-16 |
Oce Andeno Bv |
Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
|
US5223263A
(en)
|
1988-07-07 |
1993-06-29 |
Vical, Inc. |
Liponucleotide-containing liposomes
|
GB8719367D0
(en)
|
1987-08-15 |
1987-09-23 |
Wellcome Found |
Therapeutic compounds
|
EP0380558A4
(en)
|
1987-09-22 |
1991-07-31 |
The Regents Of The University Of California |
Liposomal nucleoside analogues for treating aids
|
IL91664A
(en)
|
1988-09-28 |
1993-05-13 |
Yissum Res Dev Co |
Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
|
US6132763A
(en)
|
1988-10-20 |
2000-10-17 |
Polymasc Pharmaceuticals Plc |
Liposomes
|
US5705363A
(en)
|
1989-03-02 |
1998-01-06 |
The Women's Research Institute |
Recombinant production of human interferon τ polypeptides and nucleic acids
|
US5411947A
(en)
|
1989-06-28 |
1995-05-02 |
Vestar, Inc. |
Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
|
US5194654A
(en)
|
1989-11-22 |
1993-03-16 |
Vical, Inc. |
Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
|
US5463092A
(en)
|
1989-11-22 |
1995-10-31 |
Vestar, Inc. |
Lipid derivatives of phosphonacids for liposomal incorporation and method of use
|
US5026687A
(en)
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
JPH05506230A
(ja)
|
1990-04-06 |
1993-09-16 |
ジーンラブス テクノロジイズ インコーポレイテッド |
C型肝炎ウイルスエピトープ
|
AU7872491A
(en)
|
1990-05-07 |
1991-11-27 |
Vical, Inc. |
Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
|
JPH05507279A
(ja)
|
1990-05-29 |
1993-10-21 |
ネクススター・ファーマシューティカルズ・インコーポレイテッド |
グリセロールジ―およびトリホスフェート誘導体の合成
|
WO1991019721A1
(en)
|
1990-06-13 |
1991-12-26 |
Arnold Glazier |
Phosphorous produgs
|
US6060080A
(en)
|
1990-07-16 |
2000-05-09 |
Daiichi Pharmaceutical Co., Ltd. |
Liposomal products
|
JP2599492B2
(ja)
|
1990-08-21 |
1997-04-09 |
第一製薬株式会社 |
リポソーム製剤の製造法
|
US5372808A
(en)
|
1990-10-17 |
1994-12-13 |
Amgen Inc. |
Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
|
US5149794A
(en)
|
1990-11-01 |
1992-09-22 |
State Of Oregon |
Covalent lipid-drug conjugates for drug targeting
|
US5543389A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization |
Covalent polar lipid-peptide conjugates for use in salves
|
US5256641A
(en)
|
1990-11-01 |
1993-10-26 |
State Of Oregon |
Covalent polar lipid-peptide conjugates for immunological targeting
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
US5595732A
(en)
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
US5157027A
(en)
|
1991-05-13 |
1992-10-20 |
E. R. Squibb & Sons, Inc. |
Bisphosphonate squalene synthetase inhibitors and method
|
CA2112803A1
(en)
|
1991-07-12 |
1993-01-21 |
Karl Y. Hostetler |
Antiviral liponucleosides: treatment of hepatitis b
|
US5554728A
(en)
|
1991-07-23 |
1996-09-10 |
Nexstar Pharmaceuticals, Inc. |
Lipid conjugates of therapeutic peptides and protease inhibitors
|
TW224053B
(es)
|
1991-09-13 |
1994-05-21 |
Paul B Chretien |
|
US5676942A
(en)
|
1992-02-10 |
1997-10-14 |
Interferon Sciences, Inc. |
Composition containing human alpha interferon species proteins and method for use thereof
|
US5405598A
(en)
|
1992-02-24 |
1995-04-11 |
Schinazi; Raymond F. |
Sensitizing agents for use in boron neutron capture therapy
|
JP3102945B2
(ja)
|
1992-02-27 |
2000-10-23 |
財団法人野田産業科学研究所 |
肝炎治療剤
|
US5610054A
(en)
|
1992-05-14 |
1997-03-11 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecule targeted against Hepatitis C virus
|
JP3291071B2
(ja)
|
1992-06-22 |
2002-06-10 |
イーライ・リリー・アンド・カンパニー |
アルファ−アノマーに富む1−ハロ−2−デオキシ−2,2−ジフルオロ−d−リボフラノシル誘導体の製造方法
|
US5256798A
(en)
|
1992-06-22 |
1993-10-26 |
Eli Lilly And Company |
Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
|
US5426183A
(en)
|
1992-06-22 |
1995-06-20 |
Eli Lilly And Company |
Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
CA2105112C
(en)
|
1992-09-01 |
2005-08-02 |
Thomas C. Britton |
A process for anomerizing nucleosides
|
GB9226729D0
(en)
|
1992-12-22 |
1993-02-17 |
Wellcome Found |
Therapeutic combination
|
AU6247594A
(en)
|
1993-02-24 |
1994-09-14 |
Jui H. Wang |
Compositions and methods of application of reactive antiviral polymers
|
US6180134B1
(en)
|
1993-03-23 |
2001-01-30 |
Sequus Pharmaceuticals, Inc. |
Enhanced ciruclation effector composition and method
|
CA2162574A1
(en)
|
1993-05-12 |
1994-11-24 |
Karl Y. Hostetler |
Acyclovir derivatives for topical use
|
WO1995003056A1
(fr)
|
1993-07-19 |
1995-02-02 |
Tokyo Tanabe Company Limited |
Inhibiteur de proliferation du virus de l'hepatite c
|
US7375198B2
(en)
|
1993-10-26 |
2008-05-20 |
Affymetrix, Inc. |
Modified nucleic acid probes
|
US6156501A
(en)
|
1993-10-26 |
2000-12-05 |
Affymetrix, Inc. |
Arrays of modified nucleic acid probes and methods of use
|
KR960705579A
(ko)
|
1993-11-10 |
1996-11-08 |
에릭에스. 딕커 |
개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
|
US5951974A
(en)
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
WO1995024185A1
(en)
|
1994-03-11 |
1995-09-14 |
Isis Pharmaceuticals, Inc. |
Novel pyrimidine nucleosides
|
DE4447588C2
(de)
|
1994-05-03 |
1997-11-20 |
Omer Osama Dr Dr Med |
Pflanzliches Arzneimittel zur Behandlung von chronischen und allergischen Rhino-Sino-Bronchitiden
|
CA2192950A1
(en)
|
1994-06-22 |
1995-12-28 |
Danny P.C. Mcgee |
Novel method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement
|
DE4432623A1
(de)
|
1994-09-14 |
1996-03-21 |
Huels Chemische Werke Ag |
Verfahren zur Bleichung von wäßrigen Tensidlösungen
|
US5738846A
(en)
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
US5696277A
(en)
|
1994-11-15 |
1997-12-09 |
Karl Y. Hostetler |
Antiviral prodrugs
|
US5703058A
(en)
|
1995-01-27 |
1997-12-30 |
Emory University |
Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
|
US6391859B1
(en)
|
1995-01-27 |
2002-05-21 |
Emory University |
[5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
|
WO1996023506A1
(de)
|
1995-02-01 |
1996-08-08 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung und arzneimittel, enthaltend diese nukleoside
|
GB9505025D0
(en)
|
1995-03-13 |
1995-05-03 |
Medical Res Council |
Chemical compounds
|
DE19514523A1
(de)
|
1995-04-12 |
1996-10-17 |
Schering Ag |
Neue Cytosin- und Cytidinderivate
|
US5981247A
(en)
|
1995-09-27 |
1999-11-09 |
Emory University |
Recombinant hepatitis C virus RNA replicase
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
US5767097A
(en)
|
1996-01-23 |
1998-06-16 |
Icn Pharmaceuticals, Inc. |
Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
|
GB9602028D0
(en)
|
1996-02-01 |
1996-04-03 |
Amersham Int Plc |
Nucleoside analogues
|
US5980884A
(en)
|
1996-02-05 |
1999-11-09 |
Amgen, Inc. |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
|
EP0914421A2
(en)
|
1996-02-29 |
1999-05-12 |
Immusol, Inc. |
Hepatitis c virus ribozymes
|
US5633388A
(en)
|
1996-03-29 |
1997-05-27 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5830905A
(en)
|
1996-03-29 |
1998-11-03 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5990276A
(en)
|
1996-05-10 |
1999-11-23 |
Schering Corporation |
Synthetic inhibitors of hepatitis C virus NS3 protease
|
GB9609932D0
(en)
|
1996-05-13 |
1996-07-17 |
Hoffmann La Roche |
Use of IL-12 and IFN alpha for the treatment of infectious diseases
|
US5891874A
(en)
|
1996-06-05 |
1999-04-06 |
Eli Lilly And Company |
Anti-viral compound
|
US5837257A
(en)
|
1996-07-09 |
1998-11-17 |
Sage R&D |
Use of plant extracts for treatment of HIV, HCV and HBV infections
|
US5858389A
(en)
*
|
1996-08-28 |
1999-01-12 |
Shaker H. Elsherbini |
Squalene is an antiviral compound for treating hepatitis C virus carriers
|
US5922757A
(en)
|
1996-09-30 |
1999-07-13 |
The Regents Of The University Of California |
Treatment and prevention of hepatic disorders
|
US6455690B1
(en)
|
1996-10-16 |
2002-09-24 |
Robert Tam |
L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
|
PL188660B1
(pl)
|
1996-10-16 |
2005-03-31 |
Icn Pharmaceuticals |
Purynowe L-nukleozydy, ich analogi oraz zastosowanie
|
PT1027359E
(pt)
|
1996-10-16 |
2003-09-30 |
Ribapharm Inc |
L-nucleosideos monociclicos analogos e suas utilizacoes
|
US6509320B1
(en)
|
1996-10-16 |
2003-01-21 |
Icn Pharmaceuticals, Inc. |
Purine L-nucleosides, analogs and uses thereof
|
NZ335276A
(en)
|
1996-10-18 |
2000-09-29 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
|
GB9623908D0
(en)
|
1996-11-18 |
1997-01-08 |
Hoffmann La Roche |
Amino acid derivatives
|
IL119833A
(en)
|
1996-12-15 |
2001-01-11 |
Lavie David |
Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
|
US6004933A
(en)
|
1997-04-25 |
1999-12-21 |
Cortech Inc. |
Cysteine protease inhibitors
|
EP1009732B1
(en)
|
1997-06-30 |
2003-05-21 |
MERZ + CO. GmbH & Co. |
1-amino-alkylcyclohexane nmda receptor antagonists
|
CA2294562C
(en)
|
1997-08-11 |
2005-07-26 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor peptide analogues
|
ES2287971T3
(es)
|
1997-08-11 |
2007-12-16 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
|
PT903148E
(pt)
|
1997-09-21 |
2002-02-28 |
Schering Corp |
Terapia de combinacao para a erradicacao de rna de hcv detectavel em doentes tendo infeccao cronica pelo virus da hepatite c
|
US6703374B1
(en)
|
1997-10-30 |
2004-03-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Nucleosides for imaging and treatment applications
|
US5981709A
(en)
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
US7462605B2
(en)
|
1998-01-23 |
2008-12-09 |
Celmed Oncology (Usa), Inc. |
Phosphoramidate compounds and methods of use
|
US6245750B1
(en)
|
1998-01-23 |
2001-06-12 |
Newbiotics, Inc. |
Enzyme catalyzed therapeutic agents
|
JP2002504558A
(ja)
|
1998-02-25 |
2002-02-12 |
エモリー ユニバーシテイ |
2’−フルオロヌクレオシド
|
US6787305B1
(en)
|
1998-03-13 |
2004-09-07 |
Invitrogen Corporation |
Compositions and methods for enhanced synthesis of nucleic acid molecules
|
US6475985B1
(en)
|
1998-03-27 |
2002-11-05 |
Regents Of The University Of Minnesota |
Nucleosides with antiviral and anticancer activity
|
GB9806815D0
(en)
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
ES2172288T3
(es)
|
1998-05-15 |
2002-09-16 |
Schering Corp |
Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
|
CA2334267C
(en)
|
1998-06-08 |
2009-02-17 |
F. Hoffmann-La Roche Ag |
Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
|
DE69925918T2
(de)
|
1998-07-27 |
2006-05-11 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Diketosäure-derivate als hemmstoffe von polymerasen
|
AU5475799A
(en)
|
1998-08-10 |
2000-03-06 |
Centre National De La Recherche Scientifique |
Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
AU2157000A
(en)
|
1998-12-18 |
2000-07-12 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction hcv combination therapy
|
EP1027886B1
(en)
|
1999-02-10 |
2008-07-09 |
Pfizer Products Inc. |
Pharmaceutical solid dispersions
|
IL147750A0
(en)
|
1999-07-22 |
2002-08-14 |
Newbiotics Inc |
Enzyme catalyzed therapeutic activation
|
CA2389745C
(en)
|
1999-11-04 |
2010-03-23 |
Shire Biochem Inc. |
Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
|
CN1919859A
(zh)
|
1999-11-12 |
2007-02-28 |
法玛赛特有限公司 |
2'-脱氧-l-核苷的合成
|
US6495677B1
(en)
|
2000-02-15 |
2002-12-17 |
Kanda S. Ramasamy |
Nucleoside compounds
|
EA200200778A1
(ru)
|
2000-02-18 |
2003-06-26 |
Шайре Байокем Инк. |
СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С В ОРГАНИЗМЕ ХОЗЯИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ПРОТИВ ФЛАВИВИРУСА, СОЕДИНЕНИЕ ФОРМУЛЫ Ib - АКТИВНЫЙ АГЕНТ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С ИЛИ ФЛАВИВИРУСА (ВАРИАНТЫ)
|
BR0110023A
(pt)
|
2000-04-13 |
2003-12-30 |
Pharmasset Ltd |
Derivados de nucleosìdeo 3'-ou-2' substituìdos para tratamento de infecções por vìrus da hepatite
|
WO2001081359A1
(en)
|
2000-04-20 |
2001-11-01 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
NZ547204A
(en)
|
2000-05-26 |
2008-01-31 |
Idenix Cayman Ltd |
Methods and compositions for treating flaviviruses and pestiviruses
|
EA005890B1
(ru)
|
2000-05-26 |
2005-06-30 |
Айденикс (Кайман) Лимитед |
СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
|
US6787526B1
(en)
|
2000-05-26 |
2004-09-07 |
Idenix Pharmaceuticals, Inc. |
Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
|
FR2810322B1
(fr)
|
2000-06-14 |
2006-11-10 |
Pasteur Institut |
PRODUCTION COMBINATOIRE D'ANALOGUES DE NUCLEOTIDES ET NUCLEOTIDES (XiTP)
|
MY141594A
(en)
|
2000-06-15 |
2010-05-14 |
Novirio Pharmaceuticals Ltd |
3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
|
US6815542B2
(en)
|
2000-06-16 |
2004-11-09 |
Ribapharm, Inc. |
Nucleoside compounds and uses thereof
|
UA72612C2
(en)
|
2000-07-06 |
2005-03-15 |
|
Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
|
US7169760B2
(en)
|
2000-07-21 |
2007-01-30 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
EE05366B1
(et)
|
2000-07-21 |
2010-12-15 |
Gilead Sciences, Inc |
Fosfonaatnukleotiidanaloogide eelravimid ja skriinimise meetodid nende identifitseerimiseks
|
JP2004504407A
(ja)
|
2000-07-21 |
2004-02-12 |
コルバス・インターナショナル・インコーポレイテッド |
C型肝炎ウイルスのns3−セリンプロテアーゼ阻害剤としての新規ペプチド
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
AR034127A1
(es)
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
AR039558A1
(es)
|
2000-08-21 |
2005-02-23 |
Inspire Pharmaceuticals Inc |
Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
|
US6897201B2
(en)
|
2000-08-21 |
2005-05-24 |
Inspire Pharmaceuticals, Inc. |
Compositions and methods for the treatment of glaucoma or ocular hypertension
|
US7018985B1
(en)
|
2000-08-21 |
2006-03-28 |
Inspire Pharmaceuticals, Inc. |
Composition and method for inhibiting platelet aggregation
|
US20030008841A1
(en)
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
DE10046541A1
(de)
|
2000-09-19 |
2002-03-28 |
Knoll Ag |
Mechanisch stabile darreichungsformen, enthaltend Ubichinone
|
DK1411954T3
(da)
|
2000-10-18 |
2011-03-14 |
Pharmasset Inc |
Modificerede nukleosider til behandling af virusinfektioner og abnorm cellulær proliferation
|
HUP0301444A3
(en)
|
2000-10-18 |
2007-05-29 |
Schering Corp |
The use of ribavirin-pegylated interferon alfa for the preparation of pharmaceutical compositions for the treatment of hcv infection
|
US6555677B2
(en)
|
2000-10-31 |
2003-04-29 |
Merck & Co., Inc. |
Phase transfer catalyzed glycosidation of an indolocarbazole
|
ES2263687T3
(es)
|
2000-11-20 |
2006-12-16 |
Bristol-Myers Squibb Company |
Inhibidores tripeptidicos de la hepatitis c.
|
CA2430458A1
(en)
|
2000-12-12 |
2002-06-20 |
Schering Corporation |
Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
|
AU2002230763A1
(en)
|
2000-12-13 |
2008-01-03 |
Bristol-Myers Squibb Pharma Company |
Inhibitors of hepatitis c virus ns3 protease
|
US6727366B2
(en)
|
2000-12-13 |
2004-04-27 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
|
AU2002232660A1
(en)
|
2000-12-15 |
2002-06-24 |
Pharmasset Ltd. |
Antiviral agents for treatment of flaviviridae infections
|
SI1355916T1
(sl)
|
2001-01-22 |
2007-04-30 |
Merck & Co Inc |
Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
|
US7105499B2
(en)
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
GB0112617D0
(en)
|
2001-05-23 |
2001-07-18 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
GB0114286D0
(en)
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
JP2004534830A
(ja)
|
2001-06-21 |
2004-11-18 |
グラクソ グループ リミテッド |
Hcvにおけるヌクレオシド化合物
|
NZ530000A
(en)
|
2001-07-11 |
2007-03-30 |
Vertex Pharma |
Peptidomimetic bridged bicyclic serine protease inhibitors
|
US6841566B2
(en)
|
2001-07-20 |
2005-01-11 |
Boehringer Ingelheim, Ltd. |
Viral polymerase inhibitors
|
EP2335700A1
(en)
|
2001-07-25 |
2011-06-22 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C virus polymerase inhibitors with a heterobicylic structure
|
US6962991B2
(en)
|
2001-09-12 |
2005-11-08 |
Epoch Biosciences, Inc. |
Process for the synthesis of pyrazolopyrimidines
|
EP1432721A4
(en)
|
2001-09-13 |
2008-02-20 |
Bristol Myers Squibb Co |
PROCESS FOR THE PREPARATION OF REBECCAMYCIN AND ANALOGUE THEREOF
|
WO2003024461A1
(en)
|
2001-09-20 |
2003-03-27 |
Schering Corporation |
Hcv combination therapy
|
AU2002330154A1
(en)
|
2001-09-28 |
2003-04-07 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
EP1440069B1
(en)
|
2001-11-02 |
2007-08-15 |
Glaxo Group Limited |
4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
|
GB0129945D0
(en)
|
2001-12-13 |
2002-02-06 |
Mrc Technology Ltd |
Chemical compounds
|
US7105527B2
(en)
|
2001-12-14 |
2006-09-12 |
Otto Michael J |
N4-acylcytosine nucleosides for treatment of viral infections
|
WO2003051899A1
(en)
|
2001-12-17 |
2003-06-26 |
Ribapharm Inc. |
Deazapurine nucleoside libraries and compounds
|
EP1458735A2
(en)
|
2001-12-21 |
2004-09-22 |
Micrologix Biotech, Inc. |
Anti-viral 7-deaza l-nucleosides
|
WO2003062256A1
(en)
|
2002-01-17 |
2003-07-31 |
Ribapharm Inc. |
2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
|
CA2370396A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
MXPA04007435A
(es)
|
2002-02-01 |
2004-10-11 |
Pfizer Prod Inc |
Metodo para preparar dispersiones solidas amorfas de farmacos secadas por pulverizacion utilizando inyectores a presion.
|
CA2472028C
(en)
|
2002-02-01 |
2010-03-30 |
Pfizer Products Inc. |
Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US7323453B2
(en)
|
2002-02-13 |
2008-01-29 |
Merck & Co., Inc. |
Methods of inhibiting orthopoxvirus replication with nucleoside compounds
|
US20040023901A1
(en)
|
2002-02-28 |
2004-02-05 |
Cook Phillip D. |
Nucleoside 5'-monophosphate mimics and their prodrugs
|
AU2003217863B9
(en)
|
2002-02-28 |
2009-10-29 |
Biota Scientific Management Pty Ltd |
Nucleotide mimics and their prodrugs
|
US20040014108A1
(en)
|
2002-05-24 |
2004-01-22 |
Eldrup Anne B. |
Oligonucleotides having modified nucleoside units
|
ES2304511T3
(es)
|
2002-06-04 |
2008-10-16 |
Schering Corporation |
Compuestos de pirazolo(1,5-a)pirimidina como agentes antivirales.
|
AU2003242672B2
(en)
|
2002-06-07 |
2009-12-17 |
Universitair Medisch Centrum Utrecht |
New compounds for modulating the activity of exhange proteins directly activated by camp (EPACS)
|
AU2003251524A1
(en)
|
2002-06-17 |
2003-12-31 |
Isis Pharmaceuticals, Inc. |
Carbocyclic nucleoside analogs as RNA-antivirals
|
AU2003248708A1
(en)
|
2002-06-17 |
2003-12-31 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
|
EP1551421A2
(en)
|
2002-06-21 |
2005-07-13 |
Merck & Co. Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
AU2003269892A1
(en)
|
2002-06-27 |
2004-01-19 |
Isis Pharmaceuticals, Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
CA2490200C
(en)
|
2002-06-28 |
2012-01-03 |
Idenix (Cayman) Limited |
2' and 3'-nucleoside prodrugs for treating flaviviridae infections
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
EP1536804A4
(en)
|
2002-06-28 |
2007-10-31 |
Idenix Cayman Ltd |
2'-C-METHYL-3'-O-L-VALINESTER-RIBOFURANOSYLCYTIDINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS
|
EP2799442A1
(en)
|
2002-06-28 |
2014-11-05 |
IDENIX Pharmaceuticals, Inc. |
Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections
|
CN1761677A
(zh)
|
2002-06-28 |
2006-04-19 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的修饰的2'和3'-核苷前药
|
AU2003265255A1
(en)
|
2002-07-01 |
2004-01-19 |
Finzel, Barry, C. |
Inhibitors of hcv ns5b polymerase
|
AU2003256334A1
(en)
|
2002-07-01 |
2004-01-19 |
Pharmacia And Upjohn Company |
Inhibitors of hcv ns5b polymerase
|
WO2004007512A2
(en)
|
2002-07-16 |
2004-01-22 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
CA2493816A1
(en)
|
2002-07-24 |
2004-01-29 |
Ptc Therapeutics, Inc. |
Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
|
US7323449B2
(en)
|
2002-07-24 |
2008-01-29 |
Merck & Co., Inc. |
Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
AU2003254657A1
(en)
|
2002-07-25 |
2004-02-16 |
Micrologix Biotech Inc. |
Anti-viral 7-deaza d-nucleosides and uses thereof
|
WO2004014852A2
(en)
|
2002-08-12 |
2004-02-19 |
Bristol-Myers Squibb Company |
Iminothiazolidinones as inhibitors of hcv replication
|
AU2003278816A1
(en)
|
2002-09-13 |
2004-04-30 |
Idenix (Cayman) Limited |
ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
|
JP2006505571A
(ja)
|
2002-10-15 |
2006-02-16 |
リゲル ファーマシューテイカルズ、インコーポレイテッド |
置換されたインドール及びhcv阻害剤としてのその使用
|
US20040229840A1
(en)
|
2002-10-29 |
2004-11-18 |
Balkrishen Bhat |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
HN2003000348A
(es)
|
2002-11-01 |
2008-10-14 |
Viropharma Inc |
Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
|
AU2003298658A1
(en)
|
2002-11-15 |
2004-06-15 |
Idenix (Cayman) Limited |
2'-branched nucleosides and flaviviridae mutation
|
TWI332507B
(en)
|
2002-11-19 |
2010-11-01 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
CA2509687C
(en)
|
2002-12-12 |
2012-08-14 |
Idenix (Cayman) Limited |
Process for the production of 2'-branched nucleosides
|
US7259186B2
(en)
|
2002-12-17 |
2007-08-21 |
Abbott Laboratories |
Salts of fenofibric acid and pharmaceutical formulations thereof
|
US7223785B2
(en)
|
2003-01-22 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
AU2003225705A1
(en)
|
2003-03-07 |
2004-09-30 |
Ribapharm Inc. |
Cytidine analogs and methods of use
|
US7582748B2
(en)
|
2003-03-20 |
2009-09-01 |
Microbiologica Quimica E Farmaceutical Ltd. |
Methods of manufacture of 2′-deoxy-β-L-nucleosides
|
ES2386161T3
(es)
|
2003-04-16 |
2012-08-10 |
Bristol-Myers Squibb Company |
Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
KR20060022647A
(ko)
|
2003-04-25 |
2006-03-10 |
길리애드 사이언시즈, 인코포레이티드 |
키나아제 억제 포스포네이트 유사체
|
NZ542342A
(en)
|
2003-04-25 |
2009-05-31 |
Gilead Sciences Inc |
Antiviral phosphonate analogs
|
WO2004096235A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
US20050261237A1
(en)
|
2003-04-25 |
2005-11-24 |
Boojamra Constantine G |
Nucleoside phosphonate analogs
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
WO2004096210A1
(en)
|
2003-05-01 |
2004-11-11 |
Glaxo Group Limited |
Acylated indoline and tetrahydroquinoline derivatives as hcv inhibitors
|
US20040259934A1
(en)
|
2003-05-01 |
2004-12-23 |
Olsen David B. |
Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
|
WO2004099241A1
(en)
|
2003-05-09 |
2004-11-18 |
Boehringer Ingelheim International Gmbh |
Hepatitis c virus ns5b polymerase inhibitor binding pocket
|
EP1656093A2
(en)
|
2003-05-14 |
2006-05-17 |
Idenix (Cayman) Limited |
Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
|
US20040229839A1
(en)
|
2003-05-14 |
2004-11-18 |
Biocryst Pharmaceuticals, Inc. |
Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
|
WO2004106356A1
(en)
|
2003-05-27 |
2004-12-09 |
Syddansk Universitet |
Functionalized nucleotide derivatives
|
BRPI0410846B8
(pt)
|
2003-05-30 |
2021-05-25 |
Gilead Pharmasset Llc |
nucleosídeo e composição farmacêutica compreendendo o mesmo
|
US7507859B2
(en)
|
2003-06-16 |
2009-03-24 |
Fifth Base Llc |
Functional synthetic molecules and macromolecules for gene delivery
|
RU2243972C1
(ru)
|
2003-06-26 |
2005-01-10 |
Государственный научный центр вирусологии и биотехнологии "Вектор" |
Фосфорамидаты нуклеозидных аналогов - ингибиторы репродукции вируса иммунодефицита человека
|
NZ544634A
(en)
|
2003-06-30 |
2009-10-30 |
Idenix Cayman Ltd |
Synthesis of beta-l-2-deoxy nucleosides
|
GB0317009D0
(en)
|
2003-07-21 |
2003-08-27 |
Univ Cardiff |
Chemical compounds
|
AU2004258750A1
(en)
|
2003-07-25 |
2005-02-03 |
Centre National De La Recherche Scientifique -Cnrs |
Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C
|
RU2006109491A
(ru)
|
2003-08-27 |
2006-08-10 |
Байота, Инк. (Au) |
Новые трициклические нуклеозиды или нуклеотиды в качестве терапевтических средств
|
AR045769A1
(es)
|
2003-09-18 |
2005-11-09 |
Vertex Pharma |
Inhibidores de las serina proteasas, particularmente, la proteasa ns3-ns4a del vhc (virus hepatitis c)
|
US7348389B2
(en)
|
2003-09-22 |
2008-03-25 |
E. I. Du Pont De Nemours And Company |
Method for achieving recoat adhesion over a fluorinated topcoat
|
US20050148534A1
(en)
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
KR100853579B1
(ko)
|
2003-10-14 |
2008-08-21 |
인터뮨, 인크. |
Hcv 복제 억제제로서 거대고리 카르복실산 및아실술폰아미드
|
US7491794B2
(en)
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
US7026339B2
(en)
|
2003-11-07 |
2006-04-11 |
Fan Yang |
Inhibitors of HCV NS5B polymerase
|
TW200528459A
(en)
|
2004-01-06 |
2005-09-01 |
Achillion Pharmaceuticals Inc |
Azabenzofuran substituted thioureas; inhibitors of viral replication
|
CA2554387A1
(en)
|
2004-01-28 |
2005-08-11 |
Merck & Co., Inc. |
Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
|
CA2557075A1
(en)
|
2004-02-25 |
2005-09-09 |
Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Office Of Technology Transf |
Methylation inhibitor compounds
|
US7157492B2
(en)
|
2004-02-26 |
2007-01-02 |
Wyeth |
Dibenzo chromene derivatives and their use as ERβ selective ligands
|
WO2005087788A2
(en)
|
2004-03-04 |
2005-09-22 |
The Regents Of The University Of California |
Methods for preparation of nucleoside phosphonate esters
|
CA2560897C
(en)
|
2004-03-30 |
2012-06-12 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
GB0408995D0
(en)
|
2004-04-22 |
2004-05-26 |
Glaxo Group Ltd |
Compounds
|
JP2008501802A
(ja)
|
2004-06-08 |
2008-01-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
医薬組成物
|
AU2005254057B2
(en)
|
2004-06-15 |
2011-02-17 |
Isis Pharmaceuticals, Inc. |
C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
|
AU2005256963A1
(en)
|
2004-06-23 |
2006-01-05 |
Centre National De La Recherche Scientifique |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
CA2571079A1
(en)
|
2004-06-24 |
2006-02-02 |
Merck & Co., Inc. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
US7217523B2
(en)
|
2004-07-02 |
2007-05-15 |
Regents Of The University Of Minnesota |
Nucleoside phosphoramidates and nucleoside phosphoramidases
|
CN102199181B
(zh)
|
2004-07-21 |
2014-09-17 |
吉利德制药有限责任公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
DK1778251T3
(da)
|
2004-07-27 |
2011-07-18 |
Gilead Sciences Inc |
Nukleosidphosphatkonjugater som anti-HIV-midler
|
US7348425B2
(en)
|
2004-08-09 |
2008-03-25 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
US7153848B2
(en)
|
2004-08-09 |
2006-12-26 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
WO2006021341A1
(en)
|
2004-08-23 |
2006-03-02 |
F. Hoffmann-La Roche Ag |
Antiviral 4’-azido-nucleosides
|
CA2577528A1
(en)
|
2004-08-23 |
2006-03-02 |
F. Hoffmann-La Roche Ag |
Heterocyclic antiviral compounds
|
WO2006029081A2
(en)
|
2004-09-02 |
2006-03-16 |
Neopharm, Inc. |
Nucleoside-lipid conjugates, their method of preparation and uses thereof
|
ES2769377T3
(es)
|
2004-09-14 |
2020-06-25 |
Gilead Pharmasset Llc |
Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo
|
FR2875409B1
(fr)
|
2004-09-17 |
2010-05-07 |
Sanofi Aventis |
Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
|
CA2581523A1
(en)
|
2004-09-24 |
2006-04-06 |
Idenix (Cayman) Limited |
Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus
|
RU2380101C2
(ru)
|
2004-09-30 |
2010-01-27 |
Тиботек Фармасьютикалз Лтд. |
Бициклические пиримидины, ингибирующие hcv
|
EP1804812A4
(en)
|
2004-10-21 |
2009-09-02 |
Merck & Co Inc |
FLUORINATED PYRROLO [2,3-D] PYRIMIDIN NUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS
|
CA2585079A1
(en)
|
2004-10-29 |
2006-05-11 |
Biocryst Pharmaceuticals, Inc. |
Therapeutic furopyrimidines and thienopyrimidines
|
WO2006063149A1
(en)
|
2004-12-09 |
2006-06-15 |
Regents Of The University Of Minnesota |
Nucleosides with antiviral and anticancer activity
|
WO2006065590A2
(en)
|
2004-12-16 |
2006-06-22 |
Xtl Biopharmaceuticals Inc. |
Pyridine and pyrimidine antiviral compositions
|
WO2006063717A2
(en)
|
2004-12-16 |
2006-06-22 |
Febit Biotech Gmbh |
Polymerase-independent analysis of the sequence of polynucleotides
|
EP1674104A1
(en)
|
2004-12-24 |
2006-06-28 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
|
CN100528875C
(zh)
|
2005-02-18 |
2009-08-19 |
美德(江西)生物科技有限公司 |
无结晶型态的印地普隆及其制备方法
|
WO2006093801A1
(en)
|
2005-02-25 |
2006-09-08 |
Abbott Laboratories |
Thiadiazine derivatives useful as anti-infective agents
|
AR058419A1
(es)
|
2005-02-28 |
2008-02-06 |
Gilead Sciences Inc |
Compuestos de nucleosidos triciclicos para tratar infecciones virales
|
BRPI0609650A2
(pt)
|
2005-03-25 |
2010-04-20 |
Tibotec Pharm Ltd |
inibidores heterobicìlicos de hvc
|
TW200720285A
(en)
|
2005-04-25 |
2007-06-01 |
Genelabs Tech Inc |
Nucleoside compounds for treating viral infections
|
WO2006121820A1
(en)
|
2005-05-05 |
2006-11-16 |
Valeant Research & Development |
Phosphoramidate prodrugs for treatment of viral infection
|
AR056347A1
(es)
|
2005-05-12 |
2007-10-03 |
Tibotec Pharm Ltd |
Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
|
AR054122A1
(es)
|
2005-05-12 |
2007-06-06 |
Tibotec Pharm Ltd |
Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas
|
WO2007027248A2
(en)
|
2005-05-16 |
2007-03-08 |
Valeant Research & Development |
3', 5' - cyclic nucleoside analogues for treatment of hcv
|
US8143288B2
(en)
|
2005-06-06 |
2012-03-27 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
US20060293752A1
(en)
|
2005-06-27 |
2006-12-28 |
Missoum Moumene |
Intervertebral disc prosthesis and associated methods
|
EP1924594A2
(en)
|
2005-07-25 |
2008-05-28 |
Intermune, Inc. |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
BRPI0614621A2
(pt)
|
2005-07-29 |
2011-04-12 |
Tibotec Pharm Ltd |
inibidores macrocìclicos de vìrus da hepatite c
|
DE602006019883D1
(de)
|
2005-07-29 |
2011-03-10 |
Medivir Ab |
Makrocyclische inhibitoren des hepatitis-c-virus
|
PL1919904T3
(pl)
|
2005-07-29 |
2014-06-30 |
Janssen R&D Ireland |
Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
|
EP1912997B1
(en)
|
2005-07-29 |
2011-09-14 |
Tibotec Pharmaceuticals |
Macrocyclic inhibitors of hepatitis c virus
|
JP2009504704A
(ja)
|
2005-08-15 |
2009-02-05 |
エフ.ホフマン−ラ ロシュ アーゲー |
抗ウイルス4′−置換プロヌクレオチドホスホルアミダート
|
GB0519488D0
(en)
|
2005-09-23 |
2005-11-02 |
Glaxo Group Ltd |
Compounds
|
GB0519478D0
(en)
|
2005-09-23 |
2005-11-02 |
Glaxo Group Ltd |
Compounds
|
BRPI0619563A2
(pt)
|
2005-12-09 |
2011-10-04 |
Pharmasset Inc |
nucleosìdeos antivirais
|
TW200730478A
(en)
|
2005-12-12 |
2007-08-16 |
Genelabs Tech Inc |
N-(6-membered aromatic ring)-amido anti-viral compounds
|
US7910595B2
(en)
|
2005-12-21 |
2011-03-22 |
Abbott Laboratories |
Anti-viral compounds
|
GB0602046D0
(en)
|
2006-02-01 |
2006-03-15 |
Smithkline Beecham Corp |
Compounds
|
WO2007092000A1
(en)
|
2006-02-06 |
2007-08-16 |
Bristol-Myers Squibb Company |
Inhibitors of hcv replication
|
EP1832281A1
(en)
|
2006-03-10 |
2007-09-12 |
Abbott GmbH & Co. KG |
Process for producing a solid dispersion of an active ingredient
|
AU2007215114A1
(en)
|
2006-02-14 |
2007-08-23 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
|
ATE532784T1
(de)
|
2006-02-17 |
2011-11-15 |
Pfizer Ltd |
3-deazapurinderivate als tlr7-modulatoren
|
JP2009530415A
(ja)
|
2006-03-20 |
2009-08-27 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
医薬組成物
|
US8895531B2
(en)
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
EP2029606B1
(en)
|
2006-05-25 |
2010-05-26 |
Brystol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
|
US8891379B2
(en)
|
2006-06-02 |
2014-11-18 |
Riverbed Technology, Inc. |
Traffic flow inference based on link loads and gravity measures
|
KR20140004808A
(ko)
|
2006-07-07 |
2014-01-13 |
길리애드 사이언시즈, 인코포레이티드 |
치료제의 약동학 특성의 모듈레이터
|
EP1881001A1
(en)
|
2006-07-20 |
2008-01-23 |
Tibotec Pharmaceuticals Ltd. |
HCV NS-3 serine protease inhibitors
|
US7759495B2
(en)
|
2006-08-11 |
2010-07-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7659270B2
(en)
|
2006-08-11 |
2010-02-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8303944B2
(en)
|
2006-08-11 |
2012-11-06 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8329159B2
(en)
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AU2007307057B2
(en)
|
2006-10-10 |
2011-09-15 |
F. Hoffmann La-Roche Ag |
Preparation of nucleosides ribofuranosyl pyrimidines
|
PL216525B1
(pl)
|
2006-10-17 |
2014-04-30 |
Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk |
5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
|
GB0623493D0
(en)
|
2006-11-24 |
2007-01-03 |
Univ Cardiff |
Chemical compounds
|
TWI442947B
(zh)
*
|
2006-12-07 |
2014-07-01 |
Daiichi Sankyo Co Ltd |
安定性經改善之薄膜塗覆製劑
|
WO2008079206A1
(en)
|
2006-12-20 |
2008-07-03 |
Merck & Co., Inc. |
Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
CA2673649A1
(en)
|
2007-01-05 |
2008-07-17 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
WO2008104408A2
(en)
|
2007-02-27 |
2008-09-04 |
K. U. Leuven Research & Development |
Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
US7741347B2
(en)
|
2007-05-17 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
GB0709791D0
(en)
|
2007-05-22 |
2007-06-27 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
JPWO2008156094A1
(ja)
|
2007-06-19 |
2010-08-26 |
杏林製薬株式会社 |
ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤
|
NZ582096A
(en)
|
2007-06-29 |
2012-05-25 |
Gilead Sciences Inc |
Antiviral compounds that inhibit hepatitis c virus (hcv)
|
CN101108870A
(zh)
|
2007-08-03 |
2008-01-23 |
冷一欣 |
核苷磷酸酯类化合物及制备方法和应用
|
US7728027B2
(en)
|
2007-08-08 |
2010-06-01 |
Bristol-Myers Squibb Company |
Process for synthesizing compounds useful for treating hepatitis C
|
US8629171B2
(en)
|
2007-08-08 |
2014-01-14 |
Bristol-Myers Squibb Company |
Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
|
JO2778B1
(en)
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain vehicles, installations and methods
|
KR20100090689A
(ko)
|
2007-10-19 |
2010-08-16 |
애보트 게엠베하 운트 콤파니 카게 |
N―아릴 우레아계 화합물을 함유하는 고체 분산액 생성물
|
US20090176732A1
(en)
|
2007-12-21 |
2009-07-09 |
Alios Biopharma Inc. |
Protected nucleotide analogs
|
ES2383388T3
(es)
|
2008-02-12 |
2012-06-20 |
Bristol-Myers Squibb Company |
Inhibidores del virus de la hepatitis C
|
US7704992B2
(en)
|
2008-02-13 |
2010-04-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8147818B2
(en)
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
KR101492672B1
(ko)
|
2008-02-13 |
2015-02-16 |
브리스톨-마이어스 스큅 컴퍼니 |
C형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸
|
US8227431B2
(en)
|
2008-03-17 |
2012-07-24 |
Hetero Drugs Limited |
Nucleoside derivatives
|
US20110269814A1
(en)
|
2008-03-26 |
2011-11-03 |
Alnylam Pharamaceuticals, Inc. |
2'-f modified rna interference agents
|
US8415321B2
(en)
|
2008-04-15 |
2013-04-09 |
Raymond F. Schinazi |
Nucleoside derivatives for treatment of Caliciviridae infections, including Norovirus infections
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
EP2321297A1
(en)
|
2008-07-10 |
2011-05-18 |
Prosidion Limited |
Piperidinyl gpcr agonists
|
WO2010009121A2
(en)
|
2008-07-15 |
2010-01-21 |
University Of Florida Research Foundation, Inc. |
Colon stem cells associated with colitis and colorectal cancer and methods of use
|
US7906655B2
(en)
|
2008-08-07 |
2011-03-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AU2009279520A1
(en)
|
2008-08-07 |
2010-02-11 |
Merck Sharp & Dohme Corp. |
Pharmaceutical formulations of an HCV protease inhibitor in a solid molecular dispersion
|
US20100256184A1
(en)
*
|
2008-08-13 |
2010-10-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
NZ591535A
(en)
*
|
2008-08-13 |
2012-12-21 |
Vertex Pharma |
Pharmaceutcial composition comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
US8383094B2
(en)
|
2008-10-01 |
2013-02-26 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TWI480272B
(zh)
|
2008-10-09 |
2015-04-11 |
Anadys Pharmaceuticals Inc |
藉由5,6-二氫-1h-吡啶-2-酮與一或多種其他抗病毒化合物的組合物抑制c型肝炎病毒的方法
|
US8729077B2
(en)
|
2008-11-28 |
2014-05-20 |
Glaxosmithkline Llc |
Anti-viral compounds, compositions, and methods of use
|
EP2373168A4
(en)
|
2008-12-03 |
2012-08-01 |
Presidio Pharmaceuticals Inc |
HCV NS5A SHEMMER
|
AU2009322393B2
(en)
|
2008-12-03 |
2017-02-02 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of HCV NS5A
|
NZ593647A
(en)
|
2008-12-23 |
2013-08-30 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
CN102753563A
(zh)
|
2008-12-23 |
2012-10-24 |
吉利德制药有限责任公司 |
核苷类似物
|
AU2009329867B2
(en)
|
2008-12-23 |
2015-01-29 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
US20100227801A1
(en)
|
2009-01-07 |
2010-09-09 |
Scynexis, Inc. |
Pharmaceutical compositions
|
WO2010091413A1
(en)
|
2009-02-09 |
2010-08-12 |
Enanta Pharmaceuticals, Inc. |
Linked dibenzimidazole derivatives
|
WO2010096462A1
(en)
|
2009-02-17 |
2010-08-26 |
Enanta Pharmaceuticals, Inc |
Linked diimidazole derivatives
|
TWI438200B
(zh)
|
2009-02-17 |
2014-05-21 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
UY32462A
(es)
|
2009-02-23 |
2010-09-30 |
Arrow Therapeutics Ltd |
Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
|
EP2398474A4
(en)
|
2009-02-23 |
2012-12-05 |
Presidio Pharmaceuticals Inc |
HCV NS5A SHEMMER
|
SG10201400235PA
(en)
|
2009-02-27 |
2014-07-30 |
Enanta Pharm Inc |
Hepatitis c virus inhibitors
|
LT2401272T
(lt)
|
2009-02-27 |
2017-03-27 |
Janssen Pharmaceuticals, Inc. |
Hcv makrociklinio slopiklio amorfinė druska
|
CA2755642A1
(en)
|
2009-03-20 |
2010-09-23 |
Alios Biopharma, Inc. |
Substituted nucleoside and nucleotide analogs
|
MX2011010132A
(es)
|
2009-03-27 |
2011-10-14 |
Presidio Pharmaceuticals Inc |
Inhibidores de anillo fusionado de hepatitis c.
|
RS54713B1
(en)
|
2009-03-27 |
2016-08-31 |
Merck Sharp & Dohme Corp. |
HEPATITIS VIRUS REPLICATION INHIBITORS C
|
US8709999B2
(en)
|
2009-03-27 |
2014-04-29 |
Presidio Pharmaceuticals, Inc. |
Substituted bicyclic HCV inhibitors
|
US8796466B2
(en)
|
2009-03-30 |
2014-08-05 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TWI476190B
(zh)
|
2009-03-30 |
2015-03-11 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
TW201038559A
(en)
|
2009-04-09 |
2010-11-01 |
Bristol Myers Squibb Co |
Hepatitis C virus inhibitors
|
US8143414B2
(en)
|
2009-04-13 |
2012-03-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2419404B1
(en)
|
2009-04-15 |
2015-11-04 |
AbbVie Inc. |
Anti-viral compounds
|
CN102414199B
(zh)
|
2009-04-24 |
2014-03-05 |
泰博特克药品公司 |
二芳基醚
|
US9139569B2
(en)
|
2009-05-12 |
2015-09-22 |
Merck Sharp & Dohme Corp. |
Fused tricyclic aryl compounds useful for the treatment of viral diseases
|
HUE036906T2
(hu)
|
2009-05-13 |
2018-08-28 |
|
Antivirális vegyületek
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
WO2010138791A1
(en)
|
2009-05-29 |
2010-12-02 |
Schering Corporation |
Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
|
US8138215B2
(en)
|
2009-05-29 |
2012-03-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8211928B2
(en)
|
2009-05-29 |
2012-07-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2435421A1
(en)
|
2009-05-29 |
2012-04-04 |
Schering Corporation |
Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
|
CA2737601C
(en)
|
2009-06-11 |
2014-10-21 |
Abbott Laboratories |
Anti-viral compounds
|
US8937150B2
(en)
|
2009-06-11 |
2015-01-20 |
Abbvie Inc. |
Anti-viral compounds
|
WO2010148006A1
(en)
|
2009-06-16 |
2010-12-23 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
US8221737B2
(en)
|
2009-06-16 |
2012-07-17 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
MX2012000695A
(es)
|
2009-07-16 |
2012-06-12 |
Vertex Pharma |
Análogos de bencimidazol para el tratamiento o la prevención de infecciones por flavivirus.
|
RU2538507C2
(ru)
|
2009-08-07 |
2015-01-10 |
Тиботек Фармасьютикалз |
Фенилэтинильные производные в качестве ингибиторов вируса гепатита с
|
CN102471324B
(zh)
|
2009-08-07 |
2014-12-17 |
泰博特克药品公司 |
作为丙型肝炎病毒抑制剂的双苯并咪唑衍生物
|
FR2949465B1
(fr)
|
2009-09-01 |
2011-08-12 |
Pf Medicament |
Derives chromones, leur procede de preparation et leurs applications therapeutiques
|
RU2012112824A
(ru)
|
2009-09-03 |
2013-10-10 |
Тиботек Фармасьютикалз |
Производные бис-бензимидазола
|
KR20120076343A
(ko)
|
2009-09-04 |
2012-07-09 |
글락소스미스클라인 엘엘씨 |
화합물
|
WO2011031904A1
(en)
|
2009-09-11 |
2011-03-17 |
Enanta Pharmaceuticals, Inc |
Hepatitis c virus inhibitors
|
WO2011031934A1
(en)
|
2009-09-11 |
2011-03-17 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
US8415374B2
(en)
|
2009-10-12 |
2013-04-09 |
Bristol-Myers Squibb Company |
Combinations of hepatitis C virus inhibitors
|
WO2011050146A1
(en)
|
2009-10-23 |
2011-04-28 |
Glaxosmithkline Llc |
Chemical compounds
|
UA108211C2
(uk)
|
2009-11-04 |
2015-04-10 |
Янссен Рід Айрленд |
Бензімідазолімідазольні похідні
|
US20110274648A1
(en)
|
2009-11-11 |
2011-11-10 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20110269956A1
(en)
|
2009-11-11 |
2011-11-03 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20110281910A1
(en)
|
2009-11-12 |
2011-11-17 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
JP2013512246A
(ja)
|
2009-11-25 |
2013-04-11 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
|
US20110137633A1
(en)
|
2009-12-03 |
2011-06-09 |
Abbott Laboratories |
Anti-viral compounds and methods of identifying the same
|
US8476225B2
(en)
|
2009-12-04 |
2013-07-02 |
Gilead Sciences, Inc. |
Antiviral compounds
|
EP2512480A4
(en)
|
2009-12-14 |
2013-05-15 |
Enanta Pharm Inc |
HEPATITIS C-VIRUS HEMMER
|
US8377980B2
(en)
|
2009-12-16 |
2013-02-19 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US20110152246A1
(en)
|
2009-12-18 |
2011-06-23 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
TW201136942A
(en)
|
2009-12-18 |
2011-11-01 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
|
JP2013515068A
(ja)
|
2009-12-22 |
2013-05-02 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ウイルス性疾患の治療のための縮合三環式化合物およびその使用方法
|
EP2515902A1
(en)
|
2009-12-24 |
2012-10-31 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
US8362020B2
(en)
|
2009-12-30 |
2013-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2011091446A1
(en)
|
2010-01-22 |
2011-07-28 |
Glaxosmithkline Llc |
Chemical compounds
|
CA2792121A1
(en)
|
2010-03-09 |
2011-09-15 |
Merck Sharp & Dohme Corp. |
Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
|
BR112012024884A2
(pt)
|
2010-03-31 |
2016-10-18 |
Gilead Pharmasset Llc |
síntese estereosseletiva de ativos contendo fósforo
|
US9125904B1
(en)
|
2010-05-11 |
2015-09-08 |
Achillion Pharmaceuticals, Inc. |
Biphenyl imidazoles and related compounds useful for treating HCV infections
|
WO2011146401A1
(en)
|
2010-05-17 |
2011-11-24 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
US8815858B2
(en)
|
2010-05-21 |
2014-08-26 |
Gilead Sciences, Inc. |
Heterocyclic flaviviridae virus inhibitors
|
NZ605440A
(en)
|
2010-06-10 |
2014-05-30 |
Abbvie Bahamas Ltd |
Solid compositions comprising an hcv inhibitor
|
UY33445A
(es)
|
2010-06-10 |
2012-01-31 |
Gilead Sciences Inc |
Un régimen de dosificación, métodos para tratar el virus de la hepatitis c, composición farmacéutica, compuesta, compuestos anti-hcv y kit
|
CA2809261A1
(en)
|
2010-08-26 |
2012-03-01 |
Rfs Pharma, Llc |
Potent and selective inhibitors of hepatitis c virus
|
AU2011307953B2
(en)
|
2010-09-29 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Tetracyclic indole derivatives for treating hepatitis C virus infection
|
WO2012048421A1
(en)
|
2010-10-14 |
2012-04-19 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor compounds
|
US20120107278A1
(en)
|
2010-10-29 |
2012-05-03 |
Pharmasset, Inc. |
Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
|
EP2640719B1
(en)
*
|
2010-11-17 |
2017-05-10 |
Gilead Pharmasset LLC |
Antiviral compounds
|
EP2654900A1
(en)
|
2010-12-20 |
2013-10-30 |
Gilead Sciences, Inc. |
Combinations for treating hcv
|
WO2012087976A2
(en)
|
2010-12-21 |
2012-06-28 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
EP2562223A1
(de)
|
2011-08-26 |
2013-02-27 |
Sika Technology AG |
Zweikomponentige Zusammensetzung auf Basis von silanfunktionellen Polymeren
|
ES2659216T5
(es)
|
2011-09-16 |
2021-06-09 |
Gilead Pharmasset Llc |
Métodos para el tratamiento del VHC
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
CN104383541A
(zh)
|
2011-10-21 |
2015-03-04 |
艾伯维公司 |
用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法
|
PT107924A
(pt)
|
2011-10-21 |
2014-12-03 |
Abbvie Inc |
Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
US20130109647A1
(en)
*
|
2011-10-31 |
2013-05-02 |
Gilead Pharmasset Llc |
Methods and compositions for treating hepatitis c virus
|
CN105837584B
(zh)
|
2011-11-16 |
2018-07-13 |
吉利德制药有限责任公司 |
作为抗病毒化合物的缩合的咪唑基咪唑
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
US9034832B2
(en)
|
2011-12-29 |
2015-05-19 |
Abbvie Inc. |
Solid compositions
|
US20130172239A1
(en)
*
|
2011-12-29 |
2013-07-04 |
Abbvie Inc. |
Solid compositions
|
US20130309196A1
(en)
|
2012-05-16 |
2013-11-21 |
Gilead Sciences, Inc. |
Antiviral compounds
|
US9079887B2
(en)
|
2012-05-16 |
2015-07-14 |
Gilead Sciences, Inc. |
Antiviral compounds
|
US9109001B2
(en)
|
2012-05-22 |
2015-08-18 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphoramidate prodrugs for HCV infection
|
US8969588B2
(en)
|
2012-06-05 |
2015-03-03 |
Gilead Pharmasset Llc |
Solid forms of an antiviral compound
|
US9056860B2
(en)
|
2012-06-05 |
2015-06-16 |
Gilead Pharmasset Llc |
Synthesis of antiviral compound
|
AR091279A1
(es)
|
2012-06-08 |
2015-01-21 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
UA119315C2
(uk)
|
2012-07-03 |
2019-06-10 |
Гіліад Фармассет Елелсі |
Інгібітори вірусу гепатиту с
|
US8841340B2
(en)
|
2012-08-17 |
2014-09-23 |
Gilead Sciences, Inc. |
Solid forms of an antiviral compound
|
US9233974B2
(en)
|
2012-12-21 |
2016-01-12 |
Gilead Sciences, Inc. |
Antiviral compounds
|
CN105748499B
(zh)
|
2013-01-31 |
2018-12-28 |
吉利德制药有限责任公司 |
两个抗病毒化合物的联用制剂
|
KR20140098706A
(ko)
|
2013-01-31 |
2014-08-08 |
닛토덴코 가부시키가이샤 |
에폭시 조성물 및 에폭시 수지 성형품
|
WO2014185995A1
(en)
|
2013-05-16 |
2014-11-20 |
Gilead Pharmasset Llc |
Hepatitis c treatments with sofosbuvir
|
PT3650014T
(pt)
|
2013-08-27 |
2021-12-27 |
Gilead Pharmasset Llc |
Formulação combinada de dois compostos antivirais
|
US20150064252A1
(en)
|
2013-08-27 |
2015-03-05 |
Gilead Pharmasset Llc |
Solid dispersion formulation of an antiviral compound
|
WO2015084741A2
(en)
|
2013-12-02 |
2015-06-11 |
Gilead Pharmasset Llc |
Methods of treating hepatitis c virus infection in subjects with cirrhosis
|
TWI721947B
(zh)
|
2014-06-11 |
2021-03-21 |
美商基利法瑪席特有限責任公司 |
抗病毒化合物的固態形式
|
TWI679203B
(zh)
|
2014-06-11 |
2019-12-11 |
美商基利法瑪席特有限責任公司 |
製備抗病毒化合物之方法
|
JP2016051146A
(ja)
|
2014-09-02 |
2016-04-11 |
ウシオ電機株式会社 |
光検出装置
|